Late additionStrategic

Gilead Sciences acquires Tubulis

Biotech, antibody-drug conjugates against cancer · Germany

up to $5bnPurchase price according to the source

SourcingClub was not involved in this transaction.

Gilead Sciences acquires the German biotech company Tubulis for up to $5bn, of which $3.15bn in cash and up to $1.85bn in milestone payments. Tubulis develops cancer drugs based on antibody-drug conjugates and is to continue at Gilead as its own ADC research unit.

In context

In June 2026 it is the 2nd of 2 deals in Healthcare on the Deal-Radar.

Deal-Radar editorial team · responsible:

late addition, source dated 19 Jun 2026: eqtgroup.com

Who was involved.

Buyer
Gilead Sciences
Target
Tubulis
Seller
Gesellschafter, darunter EQT Life Sciences
Type
Strategic
Country
Germany
Source dated
19/06/2026
Purchase price
up to $5bn, according to the source

Deal-Radar no. 47-215 · added in Week 47/2026, first reported on 19/06/2026 · publicly reported, no guarantee · SourcingClub was not involved in this transaction. Report an error · Sources and limits

We report publicly announced information and link the source; we accept no liability for its accuracy. No offer and no investment, legal or tax advice. The operators of linked pages are responsible for their content. We correct errors as soon as we learn of them. The context is based only on deals recorded in the Deal-Radar and is not complete.

Valuation in this industry.

5.9 to 10.0times EBITDA

  • 5.9x to 7.6xRevenue under €5m
  • 7.0x to 9.0x€5m to €50m
  • 8.2x to 10.0xover €50m

Market range for Healthcare & Medical Technology, not the price of this deal. Data basis: DUB KMU-Multiples, Q3/2026; preparation: SourcingClub.

June 2026 on the Deal-Radar.

4 of 21 deals were of the type Strategic.

  1. Buy-out8
  2. Add-on4
  3. Secondary4
  4. Strategic4
  5. Carve-out1

New deals every day. By email on Mondays.

All deals of the previous week in one email, with source and adviser.

Weekly email every Monday, in German.

Information from public sources, without guarantee and without claim to completeness. No investment or legal advice. Published on 21 November 2026.